Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Study Contact Information:
Guardant Health Clinical Trial Operations
📞 855‑698‑8887
📧 [email protected]
About the Study
This study is testing whether a type of blood test called a can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor (), tiny pieces of cancer that may be present in the bloodstream. Researchers want to learn how well this test can:
- Detect cancer recurrence early
- Predict outcomes after treatment
- Support future use of blood‑based monitoring instead of—or in addition to—imaging tests.
This Study is Open To:
This study is open to people 18 years or older with any of the following:
- Have been treated for early‑stage or high‑risk cancer with curative intent (such as surgery, radiation, and/or chemotherapy)
- Are planning to receive routine follow‑up care to monitor for recurrence
- Are willing to provide blood samples during follow‑up visits
This study includes people treated for several cancers, including:
- Bladder cancer that has invaded the muscle, or ureter or kidney pelvis cancer 2-3
- Breast cancer
- Must be considered high-risk for recurrence
- , triple-negative and may all be eligible
- Endometrial cancer 2-3
- Esophageal or gastro-esophageal junction cancers 2-3
- Gastric cancer 2-3
- Head and neck squamous cells cancers 1-4B
-
- Lung cancer
- Melanoma 2B-3 or 4 if treated with curative intent
- Ovarian or cancer
- 1C, 2 or 3
- 1A or 1B for high-grade serous or clear cell ovarian cancer
- Pancreatic cancer that is has been surgically removed or is eligible for surgical removal
- Rectal cancer after receiving pre-surgical treatment
This Study is NOT Open To:
People with any of the following are not eligible:
- Neuroendocrine cancer.
- History of another primary cancer diagnosed within 3 years of enrollment.
What the Study Involves
This study is enrolling people with different types of cancer. Check eligibility for cancer types that are eligible.
This is an observational study, which means:
- Participants do not receive a study drug.
- Participants will receive standard of care treatment and follow-up.
If you join:
- Blood samples are collected at enrollment and during routine follow‑up visits.
- Blood draws may continue for up to 5 years.
- Researchers compare blood test results with clinical outcomes, such as whether and when cancer returns.
- Participants do not receive their blood test results.
Study Contact Information:
Guardant Health Clinical Trial Operations
📞 855‑698‑8887
📧 [email protected]
Study Contact Information:
Guardant Health Clinical Trial Operations
📞 855‑698‑8887
📧 [email protected]